Opinion|Videos|July 2, 2024

Incorporating a Subcutaneous Novel Therapy into Multiple Sclerosis Treatment

Experts in multiple sclerosis discuss the potential introduction of a subcutaneous form of ocrelizumab to the market in late 2024 and how they plan to incorporate it into their treatment algorithms.

Video content above is prompted by the following questions:

  • A subcutaneous form of ocrelizumab may come to market later this year. How will you incorporate this into your treatment algorithms?
  • Will payers evaluate coverage decisions for this therapy differently than the intravenous form?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo